RBC Capital Maintains Outperform on Amgen, Raises Price Target to $332
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on Amgen (NASDAQ:AMGN) and raises the price target from $328 to $332.
June 14, 2024 | 1:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Gregory Renza maintains an Outperform rating on Amgen and raises the price target from $328 to $332.
The raised price target and maintained Outperform rating from a reputable analyst at RBC Capital is likely to positively impact Amgen's stock price in the short term as it reflects confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100